Constituyentes psicoactivos del cannabis y sus implicaciones clínicas: una revisión sistemática

• Cristina Casajuana Köguel ^[1] ; Hugo López-Pelayo ^[3] ; Mª Mercedes Balcells-Olivero ^[2] ; Joan Colom ^[4] ; Antoni Gual ^[1]
  1. [1] Institut d'Investigacions Biomèdiques August Pi i Sunyer

     Institut d'Investigacions Biomèdiques August Pi i Sunyer

     Barcelona, España

     
  2. [2] Hospital Clinic Barcelona

     Hospital Clinic Barcelona

     Barcelona, España

     
  3. [3] Fundació Clínic per la Recerca Biomèdica
  4. [4] Public Health Agency of Catalonia

  Mostrar afiliaciones +
• Localización: Adicciones: Revista de socidrogalcohol, ISSN 0214-4840, Vol. 30, Nº. 2, 2018, págs. 140-151
• Idioma: español
• DOI: 10.20882/adicciones.858
• Títulos paralelos:
  • Psychoactive constituents of cannabis and their clinical implications: a systematic review
• Enlaces
  • Texto completo  1    2  
• Dialnet Métricas: 10 Citas
• Resumen
  • español

    Objetivo Esta revisión sistemática pretende resumir la actual evidencia sobre qué cannabinoides naturalmente presentes contribuyen a la psicoactividad final del cannabis, considerando sus concentraciones registradas y su farmacodinamia en humanos.

    Metodología Siguiendo las guías PRISMA, se revisaron artículos científicos publicados antes de marzo 2016 en Medline, Scopus-Elsevier, Scopus, ISI-Web of Knowledge y COCHRANE, que cumplieran unos criterios establecidos a-priori.

    Resultados En 40 artículos científicos, se identificaron tres cannabinoides naturalmente presentes (∆-9-Tetrahydrocannabinol, ∆-8-Tetrahydrocannabinol y cannabinol) y un metabolito humano (11-OH-THC) con relevancia clínica. De éstos, el metabolito produce los efectos psicoactivos más potentes. El cannabidiol (CBD) no es psicoactivo, pero sí ejerce un efecto modulador sobre los efectos psicoactivos del cannabis. La concentración 9-THC en derivados cannábicos (hasta 40%) supera en gran medida la de otros cannabinoides (hasta 9%). La farmacodinamia descrita varía, dada la heterogeneidad en aspectos clave de la metodología (dosis, rutas de administración y experiencia previa con cannabis de los participantes).

    Conclusiones Los resultados evidencian que el 9-THC es el cannabinoide que más contribuye al efecto psicoactivo del cannabis. Otros cannabinoides psicoactivos contribuirían mínimamente, dada su menor potencia psicoactiva y su baja concentración en los derivados cannábicos. La falta de estándares metodológicos dificulta el avance en los conocimientos sobre los efectos del cannabis en la salud. Establecer una unidad estándar de cannabis basada en 9-THC ayudaría a superar estas limitaciones.

  • English

    Objective This systematic review aims to summarize current evidence on which naturally present cannabinoids contribute to cannabis psychoactivity, considering their reported concentrations and pharmacodynamics in humans.

    Design Following PRISMA guidelines, papers published before March 2016 in Medline, Scopus-Elsevier, Scopus, ISI-Web of Knowledge and COCHRANE, and fulfilling established a-priori selection criteria have been included.

    Results In 40 original papers, three naturally present cannabinoids (Δ-9- Tetrahydrocannabinol, Δ-8-Tetrahydrocannabinol and Cannabinol) and one human metabolite (11-OH-THC) had clinical relevance.

    Of these, the metabolite produces the greatest psychoactive effects.

    Cannabidiol (CBD) is not psychoactive but plays a modulating role on cannabis psychoactive effects. The proportion of 9-THC in plant material is higher (up to 40%) than in other cannabinoids (up to 9%). Pharmacodynamic reports vary due to differences in methodological aspects (doses, administration route and volunteers’ previous experience with cannabis).

    Conclusions Findings reveal that 9-THC contributes the most to cannabis psychoactivity. Due to lower psychoactive potency and smaller proportions in plant material, other psychoactive cannabinoids have a weak influence on cannabis final effects. Current lack of standard methodology hinders homogenized research on cannabis health effects. Working on a standard cannabis unit considering 9-THC is recommended.

• Referencias bibliográficas
  • Abood, M. E. y Martin, B. R. (1992). Neurobiology of marijuana abuse. Trends in Pharmacological Sciences, 13, 201– 206. doi:10.1016/0165-6147(92)90064-D.
  • Adams, I. B. y Martin, B. R. (1996). Cannabis: pharmacology and toxicology in animals and humans. Addiction, 91, 1585–1614. doi:10.1046/j.1360-0443.1996.911115852.x.
  • Appendino, G., Chianese, G. y Taglialatela-Scafati, O. (2011). Cannabinoids: Occurrence and Medicinal Chemistry. Current Medicinal Chemistry,...
  • Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., … McGuire, P. K. (2010). Opposite...
  • Borgelt, L. M., Franson, K. L., Nussbaum, A. M. y Wang, G. S. (2013). The Pharmacologic and Clinical Effects of Medical Cannabis. Pharmacotherapy:...
  • Bruci, Z., Papoutsis, I., Athanaselis, S., Nikolaou, P., Pazari, E., Spiliopoulou, C. y Vyshka, G. (2012). First systematic evaluation of...
  • Burgdorf, J. R., Kilmer, B. y Pacula, R. L. (2011). Heterogeneity in the composition of marijuana seized in California. Drug and Alcohol Dependence,...
  • Chait, L. D. y Zacny, J. P. (1992). Reinforcing and subjective effects of oral δ9-THC and smoked marijuana in humans. Psychopharmacology,...
  • Curran, V., Brignell, C., Fletcher, S., Middleton, P. y Henry, J. (2002). Cognitive and subjective dose-response effects of acute oral δ...
  • D’Souza, D. C., Ranganathan, M., Braley, G., Gueorguieva, R., Zimolo, Z., Cooper, T., … Krystal, J. (2008). Blunted psychotomimetic and amnestic...
  • Dalton, W. S., Martz, R., Lemberger, L., Rodda, B. E. y Forney, R. B. (1976). Influence of cannabidiol on delta-9-tetrahydrocannabinol effects....
  • De Souza, M. R. C., Karniol, I. G. y Ventura, D. F. (1974). Human tonal preferences as a function of frequency under δ8-tetrahydrocannabinol....
  • Dewey, W. L. (1987). Cannabinoid pharmacology. Journal of Ethnopharmacology, 20, 293–294. doi:10.1016/03788741(87)90061-4.
  • Eichler, M., Spinedi, L., Unfer-Grauwiler, S., Bodmer, M., Surber, C., Luedi, M. y Drewe, J. (2012). Heat Exposure of Cannabis sativa Extracts...
  • ElSohly, M. A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S. y Church, J. C. (2016). Changes in Cannabis Potency Over the Last 2 Decades...
  • ElSohly, M. A., Ross, S. A., Mehmedic, Z., Arafat, R., Yi, B. y Banahan, B. F. (2000). Potency trends of delta9-THC and other cannabinoids...
  • ElSohly, M. A. y Slade, D. (2005). Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sciences, 78, 539–548....
  • Englund, A., Atakan, Z., Kralj, A., Tunstall, N., Murray, R. y Morrison, P. (2016). The effect of five day dosing with THCV on THC-induced...
  • Englund, A., Morrison, P. D., Nottage, J., Hague, D., Kane, F., Bonaccorso, S., … Kapur, S. (2013). Cannabidiol inhibits THC-elicited paranoid...
  • European Monitoring Centre for Drugs and Drug Addiction. (2012). Prevelance of Cannabis use in the European Union and Norway. Lisbon (Portugal)....
  • European Monitoring Centre for Drugs and Drug Addiction. (2016). European Drug Report 2016: Trends and Developments. Luxembourg. Retrieved...
  • Folstein, M. F. y Luria, R. (1973). Reliability, validity, and clinical application of the visual analogue mood scale1. Psychological Medicine,...
  • Gaoni, Y. y Mechoulam, R. (1964). Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. Journal of the American...
  • Greenwald, M. K. y Stitzer, M. L. (2000). Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug and Alcohol...
  • Gual, A., Martos, A. R., Lligoña, A., Llopis, J. J., Lligona, A. y Llopis, J. J. (1999). Does the concept of a standard drink apply to viticultural...
  • Hall, W. (2009). The adverse health effects of cannabis use: What are they, and what are their implications for policy? International Journal...
  • Hall, W. y Degenhardt, L. (2009). Adverse health effects of non-medical cannabis use. The Lancet, 374, 1383–1391. doi:10.1016/S0140-6736(09)61037-0.
  • Haney, M., Malcolm, R. J., Babalonis, S., Nuzzo, P. A., Cooper, Z. D., Bedi, G., … Walsh, S. L. (2016). Oral Cannabidiol does not Alter the...
  • Hart, C., Ward, A., Haney, M., Comer, S., Foltin, R. y Fischman, M. (2002). Comparison of smoked marijuana and oral δ 9 -tetrahydrocannabinol...
  • Hazekamp, A., Bastola, K., Rashidi, H., Bender, J. y Verpoorte, R. (2007). Cannabis tea revisited: A systematic evaluation of the cannabinoid...
  • Journal of Ethnopharmacology, 113, 85–90. doi:10.1016/j. jep.2007.05.019.
  • Hollister, L. E. (1973). Cannabidiol and cannabinol in man. Experientia, 29, 825–826. doi:10.1007/BF01946311.
  • Hollister, L. E. (1974). Structure-Activity Relationships in Man of Cannabis Constituents, and Homologs and Metabolites of yDelta;9-Tetrahydrocannabinol....
  • Hollister, L. E. (1987). Health aspects of cannabis. Journal of Ethnopharmacology, 19, 341–342. doi:10.1016/03788741(87)90030-4.
  • Hollister, L. E. y Gillespie, H. (1975). Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol. Clinical Pharmacology...
  • Hollister, L. E. y Gillespie, H. K. (1973). Delta-8and delta-9-tetrahydrocannabinol; Comparison in man by oral and intravenous administration....
  • Hunault, C. C., Mensinga, T. T., Böcker, K. B. E., Schipper, C. M. A., Kruidenier, M., Leenders, M. E. C., … Meulenbelt, J. (2009). Cognitive...
  • Hunault, C. C., Mensinga, T. T., de Vries, I., Kelholt-Dijkman, H. H., Hoek, J., Kruidenier, M., … Meulenbelt, J. (2008). Delta-9-tetrahydrocannabinol...
  • Ilan, A. B., Gevins, A., Coleman, M., ElSohly, M. A. y de Wit, H. (2005). Neurophysiological and subjective profile of marijuana with varying...
  • Karniol, I. G. y Carlini, E. A. (1973). Comparative Studies in Man and in Laboratory Animals on delta-8 and delta-9-trans-Tetrahydrocannabinol....
  • Knight, G., Hansen, S., Connor, M., Poulsen, H., McGovern, C. y Stacey, J. (2010). The results of an experimental indoor hydroponic Cannabis...
  • Lemberger, L., Martz, R., Rodda, B., Forney, R. y Rowe, H. (1973). Comparative Pharmacology of δ9Tetrahydrocannabinol and its Metabolite,...
  • Tetrahydrocannabinol. Journal of Clinical Investigation, 52, 2411–2417. doi:10.1172/JCI107431.
  • Leweke, F. M., Mueller, J. K., Lange, B. y Rohleder, C. (2016). Therapeutic potential of cannabinoids in psychosis. Biological Psychiatry,...
  • Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., … Moher, D. (2009). The PRISMA Statement for...
  • Martin-Santos, R., Crippa, J. A., Batalla, A., Bhattacharyya, S., Atakan, Z., Borgwardt, S., … McGuire, P. K. (2012). Acute effects of a single,...
  • Mechoulam, R. (2005). Plant cannabinoids: a neglected pharmacological treasure trove. British Journal of Pharmacology, 146, 913–915. doi:10.1038/sj.bjp.0706415.
  • Mechoulam, R. y HanuÅ¡, L. (2000). A historical overview of chemical research on cannabinoids. Chemistry and Physics of Lipids, 108, 1–13....
  • Mehmedic, Z., Chandra, S., Slade, D., Denham, H., Foster, S., Patel, A. S., … ElSohly, M. a. (2010). Potency trends of δ9-THC and other cannabinoids...
  • Morgan, C. J. A., Gardener, C., Schafer, G., Swan, S., Demarchi, C., Freeman, T. P., … Curran, H. V. (2012). Sub-chronic impact of cannabinoids...
  • Morgan, C. J. A., Schafer, G., Freeman, T. P. y Curran, H. V. (2010). Impact of cannabidiol on the acute memory and psychotomimetic effects...
  • Niesink, R. J. M., Rigter, S., Koeter, M. W. y Brunt, T. M. (2015). Potency trends of δ 9 -tetrahydrocannabinol, cannabidiol and cannabinol...
  • Observatorio Español de la Droga y las Toxicomanías. (2015). Alcohol, tabaco y drogas ilegales en España. Informe 2015.
  • Pérez-Reyes. (1973). A comparison of the Pharmacological Activity in Man of Intravenously Administered Delta-9-Tetrahydrocannabinol, Cannabinol,...
  • Pijlman, F., Rigter, S., Hoek, J., Goldschmidt, H. y Niesink, R. (2005). Strong increase in total delta-THC in cannabis preparations sold...
  • Plan Nacional sobre Drogas. (2016). Encuesta sobre el uso de drogas en enseñanzas secundarias (ESTUDES) 2014/5.
  • Potter, D. J., Clark, P. y Brown, M. B. (2008). Potency of δ 9 –THC and Other Cannabinoids in Cannabis in England in 2005: Implications for...
  • Ramesh, D., Haney, M. y Cooper, Z. D. (2013). Marijuana’s dose-dependent effects in daily marijuana smokers. Experimental and Clinical Psychopharmacology,...
  • Schaefer, C. F., Gunn, C. G. y Dubowski, K. M. (1977). Dose-Related heart-rate, perceptual, and decisional changes in man following marihuana...
  • Schwope, D. M., Bosker, W. M., Ramaekers, J. G., Gorelick, D. A. y Huestis, M. A. (2012). Psychomotor Performance, Subjective and Physiological...
  • Sharma, P., Murthy, P. y Bharath, M. M. S. (2012). Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iranian Journal...
  • Stockwell, T., Blaze-Temple, D. y Walker, C. (1991). The effect of “standard drink” labelling on the ability of drinkers to pour a “standard...
  • Tsumura, Y., Aoki, R., Tokieda, Y., Akutsu, M., Kawase, Y., Kataoka, T., … Kurahashi, K. (2012). A survey of the potency of Japanese illicit...
  • Turner, C. E. (1974). Active substances in marijuana. Archivos de Investigacion Médica, 5, 135–140. Retrieved at http://www.scopus.com/inward/record....
  • United Nations Office on Drugs and Crime. (2015). World Drug Report 2015. New York: United Nations. Retrieved at https://www.unodc.org/documents/wdr2015/...
  • Urrútia, G. y Bonfill, X. (2010). Declaración PRISMA: una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis....
  • Van der Kooy, F., Pomahacova, B. y Verpoorte, R. (2008). Cannabis Smoke Condensate I: The Effect of Different Preparation Methods on Tetrahydro...
  • Van der Kooy, F., Pomahacova, B. y Verpoorte, R. (2009). Cannabis Smoke Condensate II: Influence of Tobacco on Tetrahydrocannabinol Levels....
  • Van der Pol, P., Liebregts, N., de Graaf, R., Korf, D. J., van den Brink, W. y van Laar, M. (2013). Validation of self-reported cannabis dose...
  • Volkow, N. D., Baler, R. D., Compton, W. M. y Weiss, S. R. B. (2014). Adverse Health Effects of Marijuana Use. New England Journal of Medicine,...
  • Wachtel, S., ElSohly, M. A., Ross, S., Ambre, J. y Wit, H. de. (2002). Comparison of the subjective effects of δ 9 -tetrahydrocannabinol...
  • World Health Organization. (2004). Neuroscience of Psychoactive Substance Use and Dependence. Addiction, 99, 1361–1362. doi:10.1111/j.1360-0443.2004.00906.x.
  • World Health Organization. (2016). The health and social effects of nonmedical cannabis use. Retrieved at http:// who.int/substance_abuse/publications/msbcannabis....
  • Zhornitsky, S. y Potvin, S. (2012). Cannabidiol in Humans—The Quest for Therapeutic Targets. Pharmaceuticals, 5, 529–552. doi:10.3390/ph5050529.
  • Zuardi, A. W., Shirakawa, I., Finkelfarb, E. y Karniol, I. G. (1982). Action of cannabidiol on the anxiety and other effects produced by 9-THC...
  • Zuurman, L., Roy, C., Schoemaker, R., Hazekamp, A., den Hartigh, J., Bender, J., … van Gerven, J. (2008). Effect of intrapulmonary tetrahydrocannabinol...